Subscribe
crystal light / Shutterstock.com
27 August 2024NewsAmericasLiz Hockley

Ipsen files further suit against CSPC over pancreatic cancer drug generic

Biopharma firm sues CSPC for allegedly infringing Onivyde patent issued in August | Suit follows complaint in April asserting eight patents against Conjupro’s product.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FDA prevails in Ipsen dispute over ‘biologic’ definition
30 July 2024   Biopharmaceutical company insisted its cancer treatment should be considered a biologic | Panel finds “unfairly reductive” arguments “just don’t work” | FDA correct to reject Ipsen based on faulty scientific expertise.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
FDA prevails in Ipsen dispute over ‘biologic’ definition
30 July 2024   Biopharmaceutical company insisted its cancer treatment should be considered a biologic | Panel finds “unfairly reductive” arguments “just don’t work” | FDA correct to reject Ipsen based on faulty scientific expertise.

More on this story

Americas
FDA prevails in Ipsen dispute over ‘biologic’ definition
30 July 2024   Biopharmaceutical company insisted its cancer treatment should be considered a biologic | Panel finds “unfairly reductive” arguments “just don’t work” | FDA correct to reject Ipsen based on faulty scientific expertise.

More features

Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
HLK adds CRISPR specialist as partner
UPC delivers first 'imminent infringement' decision in biosimilar dispute
AstraZeneca unit draws line under Samsung dispute